checkAd

     146  0 Kommentare BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021

    RALEIGH, N.C., April 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 6, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

    Conference Call Dial-In & Webcast Information:

      Date:  Thursday, May 6, 2021
      Time: 8:30 AM Eastern Time
      Domestic: 877-407-0789
      International: 201-689-8562
      Conference ID: 13718097
      Webcast: http://public.viavid.com/index.php?id=144116

    About BioDelivery Sciences International, Inc.
    BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.

    2021 BioDelivery Sciences International, Inc.  All rights reserved.

    Contact:
    Bob Yedid
    LifeSci Advisors
    646-597-6989
    Bob@LifeSciAdvisors.com

     





    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021 RALEIGH, N.C., April 20, 2021 (GLOBE NEWSWIRE) - BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced …